BeiGene, Ltd. 06160 2018 12 31 2018 12 31 13.09 571 XIVA 2018 12 31 2018 12 31 2018 12 31 2018 12 31 2019 1 2019 2 27 1
2019 3 312018 12 31 1995 10-Q 2019 2 28 Donald W. Glazer Michael Goller Ranjeev Krishana Thomas Malley 2
2018 2 28 2 30 2019 2 27BGNE 06160 2018 2018 zanubrutinib zanubrutinib 800 2019 2020 Zanubrutinib(BGB-3111)(BTK) BTK (FDA) (MCL) (R/R)MCL R/R (CLL) (SLL) (NDA) NMPACFDA (CDE) 3
60(ASH) R/R MCL2 60 ASHMCL 1 CLL/SLL 3 110 17p R/R(MZL) 2 Zanubrutinib 2019 R/R MCL R/R CLL/SLL NDA 20192020 zanubrutinib NDA (WM)2 NDA WM 3 1 WM MCL MCL CLL/SLL2 CLL/SLL 1 WM 3 MYD88WT (NHL) 1 CLL/SLL 1 (BGB-A317) Fc PD-1IgG4 R/R (chl) NDA 60 ASHR/R chl 2 (ESMO-IO) (HCC) (NSCLC) 1 4
(ASCO-GI) (ESCC)2 HCC2 o o 3 ESCC 3 2019 R/R chl NDA PD-L1UBC 2 NDA HCC 2 R/R chl2 2 1 4 3 Pamiparib(BGB-290) PARP 23 (SNO) R/R1/2 (HRD) (mcrpc) 2 5
Pamiparib 2019 2019 2020 2 1 1 Sitravatinib (RTKs) TAM TYRO3 Axl MER split VEGFR2 KIT RETMirati Therapeutics 15 NSCLCHCC BGB-A425TIM-3 1 4 2000KUBio 2019 20182018 12 31 ABRAXANE 3,7761.3089 2017142% 436% 2017 2017 8 31 zanubrutinib 2017 9 6
Zymeworks, Inc.Zymeworks HER2 ZW25 ZW49 Zymeworks Azymetric TM EFECT TM NDA (BLA) PD-L1IMFINZI (durvalumab) BeiGene BioAtla AstraZeneca Millennium Pharmaceuticals Pfizer 2018 2018 12 31 18.12018 9 30 212017 12 31 8.3752 20182.9185 1.9389 Zymeworks 6000 2325 3035 9.7171 8.69712018 1 7.5759 5.4772 Zymeworks Mirati Therapeutics 7000 7028 3830 7
20182018 12 31 5867 1.9822201718172.3839 2017 ABRAXANE 2018 2018 12 31 37761.3089 2017156124432017 2017 8 31 20182018 12 31 2091 673420172572.1396 20182018 12 31 3.3948 9.039920171.21973.3684 20182018 12 31 91928712017303497 2017 8 31 ABRAXANE (R&D) 2018 2018 12 31 2.57466.7901201791342.6902 2018 7900 Zymeworks 6000 PARP 190089002018 12 31 Mirati 1000 2017 2017 12 31 2018 8
2018 12 31 16095438 201710953061 (SG&A) 20182018 12 31 72491.9539 201727426260 20182018 12 31 98732742017551 1225 2018 2018 12 312.6826 6.7377 0.35 0.93 (ADS)4.52 12.15 201799329311 0.17 0.17ADS 2.19 2.23 6 2 28 7 2018 +1 (844) 461-9930 +1(478) 219-0535 +852 3011-4522 +86 400-682-8609 ID 8889396 2 28 2 304 http://ir.beigene.com/ http://hkexir.beigene.com 90 9
1,000 2018 12 31 2017 12 31 $ 1,809,222 $ 837,516 41,056 29,428 8,612 1,697,390 763,509 157,061 62,568 2,249,684 1,046,479 113,283 69,779 100,414 49,598 [1] 49,512 18,444 [2] 148,888 146,271 496,037 362,248 14,445 14,422 $ 1,753,647 $ 684,231 [1] 2018 12 31 4,079 95 [2] 2017 9 10
ADS ADS 1,000 12 313 12 3112 2018 2017 2018 2017 $ 37,762 $ 15,606 $ 130,885 $ 24,428 20,908 2,568 67,335 213,959 58,670 18,174 198,220 238,387 (9,193) (3,030) (28,705) (4,974) [1] (257,464) (91,340) (679,005) (269,018) (72,490) (27,415) (195,385) (62,602) (331) (187) (894) (250) (339,478) (121,972) (903,989) (336,844) (280,808) (103,798) (705,769) (98,457) 5,950 (527) 13,947 (4,108) (396) 9,960 1,993 11,501 (275,254) (94,365) (689,829) (91,064) 8,544 (4,915) 15,796 (2,235) $ (266,710) $ (99,280) $ (674,033) $ (93,299) 1,545 43 (264) (194) $ (268,255) $ (99,323) $ (673,769) $ (93,105) $ (0.35) $ (0.17) $ (0.93) $ (0.17) 771,982,215 590,234,853 720,753,819 543,185,460 ADS $ (4.52) $ (2.19) $ (12.15) $ (2.23) ADS ADS 59,383,247 45,402,681 55,442,601 41,783,497 [1] 20182018 12 31 79008900 11
2,200 ABRAXANE i 1995(Private Securities Litigation Reform Act of 1995) 10-Q +86 10-5895-8058 +86 10-5895-8049 ir@beigene.com media@beigene.com i ABRAXANE, REVLIMID, and VIDAZA are registered trademarks of Celgene Corporation. 12